Altretamine

DB00488

small molecule approved

Deskripsi

An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.

Struktur Molekul 2D

Berat 210.2794
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 4.7-10.2 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Human urinary metabolites were Ndemethylated homologues of altretamine with <1% unmetabolized altretamine excreted at 24 hours.

Interaksi Makanan

1 Data
  • 1. Take after a meal. Take altretamine after meals and at bedtime.

Interaksi Obat

578 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Altretamine.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Altretamine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Altretamine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Altretamine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Altretamine.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Altretamine.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Altretamine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Altretamine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Altretamine.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Altretamine.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Altretamine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Altretamine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Altretamine.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Altretamine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Altretamine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Altretamine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Altretamine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Altretamine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Altretamine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Altretamine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Altretamine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Altretamine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Altretamine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Altretamine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Altretamine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Altretamine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Altretamine.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Altretamine.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Altretamine.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Altretamine.
Cladribine Altretamine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Altretamine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Altretamine.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Altretamine.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Altretamine.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Altretamine.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Altretamine.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Altretamine.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Altretamine.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Altretamine.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Altretamine.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Altretamine.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Altretamine.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Altretamine.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Altretamine.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Altretamine.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Altretamine.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Altretamine.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Altretamine.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Altretamine.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Altretamine.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Altretamine.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Altretamine.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Altretamine.
Zidovudine The risk or severity of adverse effects can be increased when Altretamine is combined with Zidovudine.
Cisplatin The risk or severity of adverse effects can be increased when Altretamine is combined with Cisplatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Altretamine is combined with Oxaliplatin.
Cyclophosphamide The risk or severity of adverse effects can be increased when Altretamine is combined with Cyclophosphamide.
Vincristine The risk or severity of adverse effects can be increased when Altretamine is combined with Vincristine.
Fluorouracil The risk or severity of adverse effects can be increased when Altretamine is combined with Fluorouracil.
Propylthiouracil The risk or severity of adverse effects can be increased when Altretamine is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Altretamine is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Altretamine is combined with Methotrexate.
Carbamazepine The risk or severity of adverse effects can be increased when Altretamine is combined with Carbamazepine.
Vinblastine The risk or severity of adverse effects can be increased when Altretamine is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Altretamine is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Altretamine is combined with Fluocinolone acetonide.
Imatinib The risk or severity of adverse effects can be increased when Altretamine is combined with Imatinib.
Triamcinolone The risk or severity of adverse effects can be increased when Altretamine is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Altretamine is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Altretamine is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Altretamine is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Altretamine is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Altretamine is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Altretamine is combined with Daunorubicin.
Irinotecan The risk or severity of adverse effects can be increased when Altretamine is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Altretamine is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Altretamine is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Altretamine is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Altretamine is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Altretamine is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Altretamine is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Altretamine is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Altretamine is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Altretamine is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Altretamine is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Altretamine is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Altretamine is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Altretamine is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Altretamine is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Altretamine is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Altretamine is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Altretamine is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Altretamine is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Altretamine is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Altretamine is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Altretamine is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Altretamine is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Altretamine is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Altretamine is combined with Fludarabine.

Target Protein

DNA

Referensi & Sumber

Artikel (PubMed)
  • PMID: 12586589
    Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A: Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. Gynecol Oncol. 2003 Feb;88(2):118-22.
  • PMID: 14751188
    Chan JK, Loizzi V, Manetta A, Berman ML: Oral altretamine used as salvage therapy in recurrent ovarian cancer. Gynecol Oncol. 2004 Jan;92(1):368-71.
  • PMID: 11302345
    Malik IA: Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Jpn J Clin Oncol. 2001 Feb;31(2):69-73.
  • PMID: 7656502
    Damia G, D'Incalci M: Clinical pharmacokinetics of altretamine. Clin Pharmacokinet. 1995 Jun;28(6):439-48.

Contoh Produk & Brand

Produk: 3 • International brands: 1
Produk
  • Hexalen
    Capsule • 50 mg/1 • Oral • US • Approved
  • Hexalen
    Capsule • 50 mg/1 • Oral • US • Approved
  • Hexalen
    Capsule • 50 mg • Oral • Canada • Approved
International Brands
  • Hexastat — ProStrakan

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul